Total assets of $258.1B against equity of $80.5B and a debt-to-equity ratio of 1.24 suggest limited capital cushion to absorb an adverse reserve or earnings shock.
CVS Health Corp. (CVS) balance sheet — 30-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Total Assets | 258.07B | 261.06B | 253.22B | 249.73B | 228.28B | 233B | 230.72B | 222.45B | 196.46B | 95.13B | 94.46B | 92.44B | 74.19B | 71.53B | 66.22B | 64.54B | 62.17B | 61.64B | 60.96B | 54.72B | 20.57B | 15.28B | 14.55B | 10.54B | 9.65B | 8.64B | 7.95B | 7.28B | 6.69B | 5.98B | 5.69B |
| Asset Growth % | 1.38% | 3.1% | 1.4% | 9.4% | -2.03% | 0.99% | 3.72% | 13.23% | 106.51% | 0.71% | 2.19% | 24.6% | 3.72% | 8.01% | 2.6% | 3.82% | 0.86% | 1.12% | 11.4% | 165.97% | 34.62% | 5.06% | 37.97% | 9.31% | 11.68% | 8.64% | 9.27% | 8.82% | 11.83% | 5.01% | 43.72% |
| Total Investment Assets | 4M | 35.01B | 31.34B | 26.28B | 23.87B | 26.14B | 23.81B | 19.69B | 18.25B | 223M | 87M | 88M | 34M | 88M | 5M | 5M | 4M | 5M | 0 | 27.5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 132.59B | 32.87B | 28.93B | 23.02B | 21.1B | 23.02B | 20.81B | 17.31B | 15.73B | 112M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-Term Investments | 3.15B | 2.15B | 2.41B | 3.26B | 2.78B | 3.12B | 3B | 2.37B | 2.52B | 111M | 87M | 88M | 34M | 88M | 5M | 5M | 4M | 5M | 0 | 27.5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 79.39B | 74.71B | 68.64B | 67.86B | 65.63B | 60.01B | 56.37B | 50.3B | 45.24B | 31.23B | 31.04B | 29.16B | 25.98B | 25.32B | 20.16B | 18.59B | 17.71B | 17.54B | 16.53B | 14.15B | 10.4B | 8.39B | 7.92B | 6.5B | 5.98B | 5.41B | 4.94B | 4.61B | 4.35B | 3.89B | 3.53B |
| Cash & Equivalents | 11.74B | 8.51B | 8.59B | 8.2B | 12.95B | 9.41B | 7.85B | 5.68B | 4.06B | 1.7B | 3.37B | 2.46B | 2.48B | 4.09B | 1.38B | 1.41B | 1.43B | 1.09B | 1.35B | 1.06B | 530.7M | 513.4M | 392.3M | 843.2M | 700.4M | 236.3M | 337.3M | 230M | 181M | 192.5M | 471.8M |
| Receivables | 163.15B | 39.78B | 36.47B | 35.23B | 27.28B | 24.43B | 21.74B | 19.62B | 17.63B | 13.18B | 12.16B | 11.89B | 9.69B | 8.73B | 6.48B | 6.05B | 4.92B | 5.46B | 5.38B | 4.58B | 2.38B | 1.84B | 1.76B | 1.35B | 1.02B | 966.2M | 824.5M | 699.3M | 650M | 452.4M | 350.7M |
| Other Current Assets | 4.19B | 5.03B | 3.08B | 3.15B | 3.54B | 5.29B | 5.28B | 5.11B | 4.58B | 945M | 660M | 722M | 1.85B | 1.37B | 1.27B | 1.08B | 655M | 646M | 637M | 477.5M | 374.5M | 319.9M | 309.1M | 287.2M | 248.5M | 288.8M | 217.2M | 233.2M | 328M | 364.8M | 378.2M |
| Goodwill & Intangibles | 441.36B | 110.99B | 118.59B | 120.51B | 102.95B | 108.15B | 110.69B | 112.87B | 115.2B | 52.08B | 51.76B | 51.98B | 37.92B | 36.07B | 36.15B | 36.33B | 35.45B | 35.81B | 35.94B | 34.35B | 4.51B | 2.59B | 2.77B | 1.29B | 1.23B | 1.19B | 818.5M | 706.9M | 725M | 711.5M | 721.7M |
| Goodwill | 85.48B | 85.48B | 91.27B | 91.27B | 78.15B | 79.12B | 79.55B | 79.75B | 78.68B | 38.45B | 38.25B | 38.11B | 28.14B | 26.54B | 26.39B | 26.46B | 25.67B | 25.68B | 25.49B | 23.92B | 3.2B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 24.22B | 25.51B | 27.32B | 29.23B | 24.8B | 29.03B | 31.14B | 33.12B | 36.52B | 13.63B | 13.51B | 13.88B | 9.77B | 9.53B | 9.75B | 9.87B | 9.78B | 10.13B | 10.45B | 10.43B | 1.32B | 2.59B | 2.77B | 1.29B | 1.23B | 1.19B | 818.5M | 706.9M | 725M | 711.5M | 721.7M |
| PP&E (Net) | 27.55B | 28.06B | 28.94B | 30.43B | 30.75B | 32.02B | 33.34B | 32.9B | 11.35B | 10.29B | 10.18B | 9.86B | 8.84B | 8.62B | 8.63B | 8.47B | 8.32B | 7.92B | 8.13B | 5.85B | 5.33B | 3.95B | 3.51B | 2.54B | 2.22B | 1.85B | 1.74B | 1.6B | 1.35B | 1.07B | 965.5M |
| Other Assets | 7.37B | 6.91B | 8.1B | 7.91B | 7.85B | 9.8B | 9.51B | 9.06B | 8.93B | 1.42B | 1.49B | 1.44B | 1.45B | 1.51B | 1.28B | 1.16B | 688M | 374M | 369M | 367.8M | 240.5M | 223.5M | 217.4M | 211.8M | 210.5M | 177.8M | 452.3M | 359.5M | 261M | 303M | 477.6M |
| Total Liabilities | 177.39B | 185.68B | 177.49B | 173.09B | 156.51B | 157.62B | 161.01B | 158.28B | 137.91B | 57.44B | 57.63B | 55.23B | 36.22B | 33.59B | 28.57B | 26.49B | 24.43B | 25.87B | 26.39B | 23.4B | 10.66B | 6.95B | 7.56B | 4.52B | 4.45B | 4.07B | 3.64B | 3.6B | 3.58B | 3.36B | 3.5B |
| Total Debt | 75.3B | 93.59B | 82.92B | 79.39B | 70.73B | 76B | 85.04B | 89B | 73.43B | 27B | 27.53B | 27.46B | 12.89B | 13.4B | 9.83B | 10.01B | 10.06B | 11.18B | 11.75B | 10.48B | 5.06B | 2.19B | 2.84B | 1.08B | 1.11B | 1.07B | 1.15B | 1.03B | 1.06B | 755.3M | 1.18B |
| Net Debt | 63.56B | 85.08B | 74.33B | 71.19B | 57.79B | 66.59B | 77.19B | 83.32B | 69.37B | 25.31B | 24.16B | 25B | 10.41B | 9.31B | 8.45B | 8.6B | 8.63B | 10.09B | 10.4B | 9.43B | 4.53B | 1.68B | 2.45B | 233.1M | 412.7M | 836.3M | 810.7M | 796.8M | 881M | 562.8M | 712.5M |
| Long-Term Debt | 57.22B | 72.88B | 60.53B | 58.64B | 50.48B | 51.97B | 59.21B | 64.7B | 71.44B | 22.18B | 25.61B | 26.27B | 11.63B | 12.84B | 9.13B | 9.21B | 8.65B | 8.76B | 8.06B | 8.35B | 2.87B | 1.59B | 1.93B | 753.1M | 1.08B | 810.4M | 536.8M | 558.5M | 276M | 288.9M | 1.18B |
| Short-Term Debt | 3.46B | 5.8B | 5.74B | 2.97B | 1.78B | 4.21B | 5.44B | 3.78B | 1.99B | 4.82B | 1.92B | 1.2B | 1.26B | 561M | 695M | 806M | 1.41B | 2.42B | 3.7B | 2.13B | 2.19B | 595M | 916.2M | 323.2M | 36.8M | 262.2M | 611.2M | 468.3M | 786M | 466.4M | 0 |
| Total Current Liabilities | 93.1B | 88.69B | 84.61B | 79.19B | 69.42B | 67.81B | 62.02B | 53.3B | 44.01B | 30.65B | 26.25B | 23.17B | 19.03B | 15.43B | 14.15B | 11.96B | 11.07B | 12.3B | 13.49B | 10.77B | 7B | 4.58B | 4.86B | 3.49B | 3.11B | 3.07B | 2.96B | 2.89B | 3.13B | 2.91B | 2.12B |
| Accounts Payable | 17.88B | 59.38B | 15.89B | 14.9B | 14.84B | 12.54B | 11.14B | 10.49B | 8.93B | 8.86B | 7.95B | 7.49B | 6.55B | 5.55B | 5.07B | 4.37B | 4.03B | 3.56B | 3.8B | 3.59B | 2.52B | 2.47B | 2.28B | 1.67B | 1.71B | 1.54B | 1.35B | 1.45B | 1.29B | 1.23B | 1.05B |
| Deferred Revenue | 0 | 62M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 17.76B | 23.42B | 1.18B | 2.47B | 2.82B | 5.6B | 5.83B | 4.82B | 4.88B | 23M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.48B | 346.3M | 0 | 0 | 0 | 0 | 0 | 1B | 967.4M | 1.06B | 1.21B | 1.08B |
| Deferred Taxes | 22.76B | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 0 | 0 | 0 | 1000K | 0 | 1000K | 1000K | 1000K | 1000K | 0 | 1000K |
| Other Liabilities | 10.5B | -2.16B | 13.64B | 14.92B | 15.79B | 13.39B | 14.24B | 14.06B | 14.78B | 1.61B | 1.55B | 1.58B | 1.53B | 1.42B | 1.5B | 1.48B | 1.06B | 1.14B | 1.14B | 857.9M | 781.1M | 774.2M | 774.9M | 237.4M | 266.1M | 158.6M | 116M | 120.1M | 142M | 164.8M | 140.8M |
| Total Equity | 80.69B | 75.38B | 75.73B | 76.64B | 71.77B | 75.38B | 69.7B | 64.17B | 58.54B | 37.7B | 36.83B | 37.2B | 37.96B | 37.94B | 37.65B | 38.05B | 37.73B | 35.77B | 34.57B | 31.32B | 9.92B | 8.33B | 6.99B | 6.02B | 5.2B | 4.57B | 4.3B | 3.68B | 3.11B | 2.61B | 2.2B |
| Equity Growth % | 13.62% | -0.46% | -1.18% | 6.78% | -4.79% | 8.15% | 8.62% | 9.61% | 55.31% | 2.34% | -0.99% | -2% | 0.07% | 0.76% | -1.05% | 0.84% | 5.5% | 3.45% | 10.38% | 215.82% | 19.04% | 19.24% | 16.03% | 15.87% | 13.8% | 6.09% | 16.98% | 18.28% | 18.99% | 19.04% | 33.69% |
| Shareholders Equity | 80.5B | 75.21B | 75.56B | 76.46B | 71.47B | 75.08B | 69.39B | 63.86B | 58.23B | 37.69B | 36.83B | 37.2B | 37.96B | 37.94B | 37.65B | 38.05B | 37.7B | 35.77B | 34.57B | 31.32B | 9.92B | 8.33B | 6.99B | 6.02B | 5.2B | 4.57B | 4.3B | 3.68B | 3.11B | 2.61B | 2.2B |
| Minority Interest | 192M | 168M | 170M | 175M | 300M | 306M | 312M | 306M | 318M | 4M | 4M | 7M | 5M | 0 | 0 | 30M | 34M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | 66.71B | 61.2B | 62.84B | 61.6B | 56.4B | 54.91B | 49.64B | 45.11B | 40.91B | 43.56B | 38.98B | 35.51B | 31.85B | 28.49B | 25B | 22.09B | 19.3B | 16.36B | 13.1B | 10.29B | 7.97B | 6.74B | 5.65B | 4.85B | 4.1B | 3.49B | 3.18B | 2.54B | 2.02B | 1.73B | 1.59B |
| Common Stock | 18M | 18M | 18M | 48.99B | 48.19B | 47.38B | 46.51B | 45.97B | 45.44B | 32.1B | 17M | 17M | 17M | 17M | 17M | 16M | 16M | 16M | 16M | 15.9M | 8.5M | 8.4M | 8.3M | 4.1M | 4.1M | 4.1M | 4.1M | 4M | 4M | 0 | 0 |
| Accumulated OCI | -595M | 406M | -120M | -297M | -1.26B | 965M | 1.41B | 1.02B | 102M | -165M | -305M | -358M | -217M | -149M | -181M | -172M | -143M | -135M | -143M | -395.5M | -154.7M | -204.3M | -196.4M | -200.1M | -239M | -219.9M | -240.6M | -257M | -271M | 0 | 0 |
| Return on Equity (ROE) | 14.1% | 2.34% | 6.06% | 11.24% | 5.86% | 11.03% | 10.73% | 10.81% | -1.23% | 17.77% | 14.36% | 13.93% | 12.24% | 12.15% | 10.21% | 9.14% | 9.32% | 10.51% | 9.75% | 12.79% | 15% | 15.99% | 14.13% | 15.1% | 14.68% | 9.32% | 18.69% | 18.7% | 13.43% | 3.69% | 10.85% |
| Return on Assets (ROA) | 4.31% | 0.69% | 1.83% | 3.49% | 1.87% | 3.45% | 3.17% | 3.17% | -0.41% | 6.99% | 5.69% | 6.29% | 6.37% | 6.67% | 5.91% | 5.46% | 5.54% | 6.03% | 5.55% | 7% | 7.64% | 8.21% | 7.32% | 8.39% | 7.84% | 4.98% | 9.8% | 9.1% | 6.07% | 1.52% | 4.31% |
| Equity / Assets | 31.27% | 28.87% | 29.91% | 30.69% | 31.44% | 32.35% | 30.21% | 28.85% | 29.8% | 39.62% | 38.99% | 40.25% | 51.17% | 53.04% | 56.86% | 58.95% | 60.7% | 58.03% | 56.72% | 57.24% | 48.2% | 54.51% | 48.03% | 57.12% | 53.88% | 52.88% | 54.15% | 50.58% | 46.53% | 43.73% | 38.58% |
| Debt / Equity | 0.93x | 1.24x | 1.09x | 1.04x | 0.99x | 1.01x | 1.22x | 1.39x | 1.25x | 0.72x | 0.75x | 0.74x | 0.34x | 0.35x | 0.26x | 0.26x | 0.27x | 0.31x | 0.34x | 0.33x | 0.51x | 0.26x | 0.41x | 0.18x | 0.21x | 0.23x | 0.27x | 0.28x | 0.34x | 0.29x | 0.54x |
| Book Value per Share | 62.50 | 59.31 | 60.01 | 59.41 | 54.25 | 56.72 | 53.04 | 49.17 | 56.08 | 36.81 | 34.14 | 33.04 | 32.47 | 30.94 | 29.42 | 28.25 | 27.40 | 24.67 | 23.54 | 22.83 | 11.62 | 9.90 | 8.50 | 7.45 | 6.41 | 5.73 | 5.39 | 4.50 | 3.84 | 3.31 | 5.15 |
| Tangible BV per Share | -22.47 | -28.01 | -33.97 | -34.01 | -23.57 | -24.65 | -31.20 | -37.32 | -54.27 | -14.05 | -13.83 | -13.13 | 0.04 | 1.52 | 1.18 | 1.28 | 1.66 | -0.03 | -0.93 | -2.21 | 6.33 | 6.82 | 5.13 | 5.85 | 4.89 | 4.23 | 4.36 | 3.64 | 2.94 | 2.41 | 3.46 |
Quick answers to the most common questions about buying CVS stock.
As of 2025, CVS Health Corp. (CVS) had total assets of $261.06B including $74.71B in current assets.
CVS Health Corp. (CVS) carries total debt of $93.59B, offset by $10.66B in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
CVS Health Corp. (CVS) has total shareholders' equity (book value) of $75.21B ($59.31 book value per share). Book value represents the net worth of the company belonging to common stock holders.
CVS Health Corp. (CVS) reported a current ratio of 0.84x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Reserve adequacy and leverage pressure
Metrics are mathematically derived from official filings.
Equity Rebuild Lags Asset Expansion
According to recent SEC filings, CVS total assets moved from $253.0B in 2026Q1 to $258.1B in 2026Q3 while equity rose from $77.5B to $80.5B, suggesting the balance sheet is growing without a corresponding acceleration in retained capital generation.
The gap between asset growth and equity growth implies that much of the expansion is funded by liabilities, which stood at $177.4B in 2026Q3. Equity has recovered from the $72.9B trough in 2025Q3, but the pace of rebuilding appears modest relative to the scale of the balance sheet. Investors should monitor whether the balance sheet strengthens through earnings retention or remains dependent on reserve and debt growth.
Claims Reserves Track Elevated Loss Ratios
Based on EDBL's reported figures, CVS claims and loss balances reached $93.5B in 2026Q3 with a loss ratio of 86.3%, up from 84.4% in 2026Q1, indicating reserve intensity has risen alongside premium-driven exposure.
A loss ratio in the mid-80s leaves a narrow margin before the combined ratio, which reached 96.7%, approaches breakeven. The rise in claims balances relative to the prior period may reflect higher utilization rather than reserve strengthening, though the data cannot distinguish the two. Investors should monitor prior-year development disclosures to assess whether current reserves are adequate.
Thin Capital Buffer Against Leverage
As reported in financial statements, CVS carries a debt-to-equity ratio of 1.24 against an equity base of $80.5B, which leaves limited capacity to absorb an adverse reserve or earnings shock without further balance sheet strain.
Leverage at this level constrains flexibility for buybacks or acquisitions, and the modest 2.7% ROE in 2026Q3 suggests the equity base is not generating strong returns. Statutory RBC data is not provided, so capital adequacy relative to regulatory thresholds cannot be assessed directly. The most prudent reading is that capital is adequate for current operations but offers little cushion for a sustained deterioration in medical costs.
Reserve Timing Could Mask Underlying Risk
Based on EDBL's reported figures, the 2025Q3 combined ratio of 103.1% and net loss of $4.0B contrast with a 2026Q3 rebound, suggesting reported balance sheet recovery may depend on reserve timing that is not visible in summary figures.
The rapid swing in combined ratio and earnings implies that reserve estimates may have been adjusted between quarters, which can flatter or depress reported equity. If the recent improvement reflects favorable development rather than underlying cost containment, the apparent strengthening of the balance sheet could prove temporary. This warrants further investigation through reserve development tables before drawing firm conclusions about durable solvency.